Association Between Smoking History and Overall Survival in Patients Receiving Pembrolizumab for First-Line Treatment of Advanced Non–Small Cell Lung Cancer
Sign Up to like & getrecommendations! Published in 2022 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2022.14046
Abstract: This cohort study compares the overall survival between patients who currently or formerly smoked with patients who never smoked and initiated pembrolizumab monotherapy as first-line treatment for advanced non–small lung cancer. read more here.
Keywords: first line; treatment advanced; overall survival; line treatment ... See more keywords
Mode of progression after first line treatment correlates with outcome of chronic lymphocytic leukemia (CLL)
Sign Up to like & getrecommendations! Published in 2019 at "American Journal of Hematology"
DOI: 10.1002/ajh.25561
Abstract: In CLL, progressive disease (PD) following remission after first line treatment can present with varying phenotypes. We hypothesized that the mode of PD correlates with clinical outcomes. Data from three phase III trials of the… read more here.
Keywords: cll; first line; group; line treatment ... See more keywords
XELOX doublet regimen versus EOX triplet regimen as first‐line treatment for advanced gastric cancer: An open‐labeled, multicenter, randomized, prospective phase III trial (EXELOX)
Sign Up to like & getrecommendations! Published in 2022 at "Cancer Communications"
DOI: 10.1002/cac2.12278
Abstract: There is no consensus on whether triplet regimen is better than doublet regimen in the first‐line treatment of advanced gastric cancer (AGC). We aimed to compare the efficacy and safety of oxaliplatin plus capecitabine (XELOX)… read more here.
Keywords: doublet regimen; triplet regimen; regimen first; first line ... See more keywords
Second‐line treatment options in advanced thymic carcinoma after failure of platinum‐based chemotherapy: A multicenter retrospective study
Sign Up to like & getrecommendations! Published in 2022 at "Cancer Medicine"
DOI: 10.1002/cam4.5053
Abstract: Currently there is no standard therapy recommended for second‐line treatment for thymic carcinoma. Our study compared multidrug chemotherapy, single‐agent chemotherapy, and PD‐1 inhibitors in patients diagnosed with advanced thymic carcinoma who had previous platinum‐based chemotherapy… read more here.
Keywords: advanced thymic; thymic carcinoma; line treatment; second line ... See more keywords
Immune‐related adverse events of a PD‐L1 inhibitor plus chemotherapy versus a PD‐L1 inhibitor alone in first‐line treatment for advanced non–small cell lung cancer: A meta‐analysis of randomized control trials
Sign Up to like & getrecommendations! Published in 2020 at "Cancer"
DOI: 10.1002/cncr.33270
Abstract: The addition of chemotherapy to a programmed death 1/programmed death ligand 1 (PD‐L1) inhibitor is a more effective option as a first‐line treatment for advanced non–small cell lung cancer (NSCLC). It might also inhibit an… read more here.
Keywords: chemotherapy; inhibitor; first line; versus ... See more keywords
PD‐(L)1 inhibitors vs. chemotherapy vs. their combination in front‐line treatment for NSCLC: An indirect comparison
Sign Up to like & getrecommendations! Published in 2019 at "International Journal of Cancer"
DOI: 10.1002/ijc.32366
Abstract: We comprehensively compared the therapeutic effects and safety of PD‐1/L1 antibodies (I), chemotherapy (C) or their combination (I + C) as first‐line treatments for advanced NSCLC. Online databases were searched to identify RCTs. Survival outcomes and safety… read more here.
Keywords: chemotherapy combination; combination; treatment; line treatment ... See more keywords
Synthesizing studies for comparing different treatment sequences in clinical trials
Sign Up to like & getrecommendations! Published in 2022 at "Statistics in Medicine"
DOI: 10.1002/sim.9559
Abstract: With advances in cancer treatments and improved patient survival, more patients may go through multiple lines of treatment. It is of clinical importance to choose a sequence of effective treatments (eg, lines of treatment) for… read more here.
Keywords: clinical trials; comparing different; line; line treatment ... See more keywords
Ponatinib as second-line treatment in chronic phase chronic myeloid leukemia patients in real-life practice
Sign Up to like & getrecommendations! Published in 2018 at "Annals of Hematology"
DOI: 10.1007/s00277-018-3337-2
Abstract: Scarce information is available on the use of ponatinib as second-line treatment in chronic phase chronic myeloid leukemia (CP-CML) patients resistant and/or intolerant to prior tyrosine kinase inhibitor (TKI) therapy. We collected data from 29… read more here.
Keywords: line; chronic phase; treatment; line treatment ... See more keywords
Intermittent versus continuous first-line treatment for HER2-negative metastatic breast cancer: the Stop & Go study of the Dutch Breast Cancer Research Group (BOOG)
Sign Up to like & getrecommendations! Published in 2018 at "Breast Cancer Research and Treatment"
DOI: 10.1007/s10549-018-4906-8
Abstract: PurposeWe determined if intermittent first-line treatment with paclitaxel plus bevacizumab was not inferior to continuous treatment in patients with HER2-negative, advanced breast cancer.MethodsPatients were randomized to 2 × 4 cycles or continuous 8 cycles of paclitaxel plus… read more here.
Keywords: first line; treatment; line treatment; breast cancer ... See more keywords
Phase I/II study of everolimus combined with mFOLFOX-6 and bevacizumab for first–line treatment of metastatic colorectal cancer
Sign Up to like & getrecommendations! Published in 2018 at "Investigational New Drugs"
DOI: 10.1007/s10637-018-0645-2
Abstract: SummaryBackground This phase I/II trial evaluated toxicity and antitumor activity of everolimus plus mFOLFOX6 + bevacizumab for first-line treatment of metastatic colorectal cancer (mCRC). Methods A phase I, modified 3 + 3 Fibonacci schema determined the maximum tolerated dose… read more here.
Keywords: first line; phase; line treatment; bevacizumab first ... See more keywords
Efficacy of apatinib combined with FOLFIRI in the first-line treatment of patients with metastatic colorectal cancer
Sign Up to like & getrecommendations! Published in 2022 at "Investigational New Drugs"
DOI: 10.1007/s10637-021-01205-3
Abstract: Objective. To evaluate the efficacy and safety of apatinib combined with FOLFIRI in the first-line treatment of advanced metastatic colorectal cancer (mCRC) and explore potential factors of efficacy. Methods. Twenty mCRC patients treated at Affiliated… read more here.
Keywords: folfiri first; line treatment; apatinib combined; first line ... See more keywords